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Purpose
To evaluate the feasibility of MRgFUS ablation in
selected pancreatic and hepatic primary tumors.
Materials and methods
After giving their informed consent 5 patients with his-
tologically proven unresectable pancreatic adenocarci-
noma and 1 patient with unresectable right lobe HCC
(4 males, 2 females; age range 58-72) underwent
MRgFUS treatment on a dedicated 3T unit featuring the
ExAblate 2100 system (InSightec). The system is com-
posed by a 200-element transducer located within the
MR table. The MR guidance allows a detailed depiction
and visualization of the lesion; moreover, the use of the
proton resonance frequency (PRF) shift method allows a
real time monitoring of the temperature inside the tar-
get lesion and the adjacent anatomical structures, in
order to ensure adequate tissue ablation and safe abla-
tion margins. The treatment was performed in general
anesthesia with breath control. After the procedure,
gadolinium-enhanced gradient echo T1-weighted
sequences were performed in order to evaluate the
ablated area and the absence of possible local complica-
tions. Clinical and imaging follow-up was performed
with both MR and CT at 3 and 6 months after treat-
ment respectively for the patient with HCC and those
with pancreatic cancer.
Results
Treatment was successfully performed in all patients with-
out any adverse events during or after the procedure. MR
images acquired immediately after treatment demonstrated
necrosis of ablated area within the lesion in all cases; in
particular the HCC was completely non-enhancing. At
short term clinical follow-up, all the patients with pancrea-
tic cancer referred reduction of pain symptoms due to infil-
tration of the celiac plexus. However follow-up imaging
demonstrated recurrence of pathologic tissue within the
ablated area, even if there was no local progression of the
disease. Two patients with pancreatic cancer underwent
radiotherapy after treatment, while the remaining one
underwent another MRgFUS ablation.
Conclusions
Our preliminary clinical experience suggests that
MRgFUS is a feasible and repeatable ablative technique
in patients with unresectable and device-accessible hepa-
tic and pancreatic lesions.
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